Project Bioshield Act | Wikipedia audio article
Channel: wikipedia tts
Date: 2019-01-13

This is an audio version of the Wikipedia Article:
https://en.wikipedia.org/wiki/Project_Bioshield_Act


00:01:53 1 Provisions
00:09:23 2 Act accomplishments
00:10:59 3 Acquired vaccines
00:12:57 4 Related legislation
00:13:33 5 Recent news
00:15:57 6 Published literature
00:19:44 7 Challenges and criticism
00:21:53 7.1 PhRMA
00:23:00 8 See also



Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago.

Learning by listening is a great way to:
- increases imagination and understanding
- improves your listening skills
- improves your own spoken accent
- learn while on the move
- reduce eye strain

Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone.

Listen on Google Assistant through Extra Audio:
https://assistant.google.com/services/invoke/uid/0000001a130b3f91
Other Wikipedia audio articles at:
https://www.youtube.com/results?search_query=wikipedia+tts
Upload your own Wikipedia articles through:
https://github.com/nodef/wikipedia-tts
Speaking Rate: 0.8270145171911384
Voice name: en-US-Wavenet-D


"I cannot teach anybody anything, I can only make them think."
- Socrates


SUMMARY
=======
The Project Bioshield Act was an act passed by the United States Congress in 2004 calling for $5 billion for purchasing vaccines that would be used in the event of a bioterrorist attack. This was a ten-year program to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. A key element of the Act was to allow stockpiling and distribution of vaccines which had not been tested for safety or efficacy in humans, due to ethical concerns.  Efficacy of such agents cannot be directly tested in humans without also exposing humans to the chemical, biological, or radioactive threat being treated, so   testing follows the FDA Animal Rule for pivotal animal efficacy.Since the 2001 terrorist attacks, the United States government has allocated nearly $50 billion to address the threat of biological weapons.  U.S. funding for bioweapons-related activities focuses primarily on research for and acquisition of medicines for defense. Funding also goes toward stockpiling protective equipment, increased surveillance and detection of biological agents, and improving state and hospital preparedness.  The increase in this type of funding is mainly for   Project BioShield.  Significant funding also goes to Biomedical Advanced Research and Development Authority (BARDA), part of HHS. Funding for activities aimed at prevention has more than doubled 2007 and is distributed to 11 federal agencies.  Efforts toward cooperative international action are part of the project.